文献速递产科

产后接受治疗性抗凝治疗女性并发症的评估

Evaluation of Complications in Postpartum Women Receiving Therapeutic Anticoagulation.
PubMed 文献 · Obstet Gynecol · 2020-01-01

这项多中心回顾性队列研究纳入2003至2015年间232例产后96小时内接受治疗性抗凝的女性,评估其与大出血及伤口并发症的关联。剖宫产者主要并发症发生率为8.4%(7/83),阴道分娩者为6.0%(9/149),差异无统计学意义(P=.490);总并发症在剖宫产者中为15.7%(13/83),高于阴道分娩者的6.0%(9/149)(P=.016)。并发症与更早恢复抗凝相关,阴道分娩在9.25小时前、剖宫产在15.1小时前恢复者并发症比例更高。

要点

  • 产后96小时内治疗性抗凝者主要并发症:剖宫产8.4%(7/83),阴道分娩6.0%(9/149),P=.490。
  • 总并发症剖宫产15.7%(13/83)高于阴道分娩6.0%(9/149),P=.016。
  • 并发症者恢复抗凝的中位延迟更短:剖宫产12 vs 33小时(P=.033),阴道分娩6 vs 19小时(P=.006)。

核心结论

  • 产后早期治疗性抗凝女性中,剖宫产主要并发症发生率为8.4%(7/83),阴道分娩为6.0%(9/149)。
  • 并发症与更早恢复治疗性抗凝相关,尤其是阴道分娩在9.25小时前、剖宫产在15.1小时前恢复者。

研究设计与样本

  • 多中心回顾性队列研究,评估产后治疗性抗凝与主要并发症(出血性和伤口并发症)的关联。
  • 2003年至2015年连续纳入232例产后96小时内接受治疗性抗凝的女性;其中91例接受普通肝素,138例接受低分子量肝素,3例接受其他抗凝药。

主要发现

  • 主要复合结局(需输血、住院、容量复苏、转入重症监护室或手术的大出血并发症及主要伤口并发症)剖宫产7/83(8.4%) vs 阴道分娩9/149(6.0%),P=.490。
  • 总并发症(包括主要和次要出血及伤口并发症)剖宫产13/83(15.7%) vs 阴道分娩9/149(6.0%),P=.016。
  • 有并发症与无并发症者相比,恢复抗凝的中位延迟:剖宫产12 vs 33小时(P=.033),阴道分娩6 vs 19小时(P=.006)。
  • 阴道分娩中,抗凝在产后9.25小时前开始者并发症8/51(15.7%),9.25小时后开始者1/98(1.0%)。
  • 剖宫产中,抗凝在15.1小时前开始者并发症7/21(33.3%),15.1小时后开始者6/62(9.7%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate complications associated with early postpartum therapeutic anticoagulation. METHODS: A multicenter retrospective cohort study was done to evaluate the association between therapeutic anticoagulation postpartum and major complications (hemorrhagic and wound complications). Secondary outcomes included minor complications, risk factors associated with total complications (including the time to therapeutic anticoagulation resumption after delivery) and recurrent thrombotic events within 6 weeks postpartum. RESULTS: From 2003 to 2015, 232 consecutive women were treated with therapeutic anticoagulation within 96 hours postpartum; among those treated, 91 received unfractionated heparin, 138 received low-molecular-weight heparin, and three received other anticoagulants. The primary outcome, a composite of major hemorrhagic complications (requiring transfusion, hospitalization, volume resuscitation, transfer to intensive care unit, or surgery) and major wound complications, occurred in 7 of 83 (8.4%) for cesarean deliveries and 9 of 149 (6.0%) for vaginal deliveries (P=.490). Total complications (including major and minor hemorrhagic and wound complications) occurred in 13 of 83 (15.7%) for cesarean deliveries compared with 9 of 149 (6.0%) for vaginal deliveries (P=.016). When comparing cases associated with and without complications, the median delay before resuming anticoagulation was significantly shorter for both cesarean (12 vs 33 hours, P=.033) and vaginal deliveries (6 vs 19 hours, P=.006). For vaginal deliveries, 8 of 51 (15.7%) women had complications when anticoagulation was started before 9.25 hours postpartum, compared with 1 of 98 (1.0%) when started after 9.25 hours. For cesarean deliveries, 7 of 21 (33.3%) of women experienced complications compared with 6 of 62 (9.7%) if anticoagulation was started before or after 15.1 hours, respectively. Two (0.9%) episodes of venous thromboembolism occurred within 6 weeks postpartum. CONCLUSION: Among postpartum women who received early therapeutic anticoagulation, major complications occurred in 8.4% for cesarean deliveries and 6.0% for vaginal deliveries. Complications were associated with earlier resumption of therapeutic anticoagulation, particularly before 9.25 hours for vaginal deliveries and before 15.1 hours for cesarean deliveries.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Côté-Poirier G, Bettache N, Côté AM, et al. Evaluation of Complications in Postpartum Women Receiving Therapeutic Anticoagulation. Obstet Gynecol. 2020. PMID: 32649504. doi:10.1097/AOG.0000000000003971

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。